Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Bad Bramstedt – page 43

1 461 clinical trials in Bad Bramstedt, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Bad Bramstedt at a glance
1 461
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 461 trials in Bad Bramstedt

Open in trial search

Study on Long-Term Safety and Effects of DNL310 for Patients with Mucopolysaccharidosis Type II (MPS II)

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Tividenofusp alfa
  • Sponsor:Denali Therapeutics Inc.

Study on Monitoring Untreated Multiple Myeloma in Patients Using Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone or a New Drug Combination

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Emn Trial Office S.r.l. Impresa Sociale

Study of Venetoclax, Ibrutinib, and Rituximab or Bendamustine Combination for Patients with Untreated Mantle Cell Lymphoma Not Suitable for High-Dose Therapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bendamustine
  • Sponsor:Universitatsmedizin der Johannes Gutenberg-Universitat Mainz KöR

Study on Venetoclax and Obinutuzumab for Adults with Recurring Chronic Lymphocytic Leukemia

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Obinutuzumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Study on Stopping CDK4/6 Inhibitors in Patients with Metastatic HR Positive, HER2 Negative Breast Cancer Using Abemaciclib, Letrozole, and Fulvestrant

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH

Study on Advanced Laryngeal and Hypopharyngeal Cancer: Comparing Docetaxel, Cisplatin, and Pembrolizumab for Patients Eligible for Laryngectomy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:University of Leipzig

Long-term Follow-up Study for Patients with Solid and Blood Cancers Treated with Brexucabtagene Autoleucel or Axicabtagene Ciloleucel

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:KITE-363
  • Sponsor:Kite Pharma Inc.

Study on Vitrectomy, Alteplase, and Aflibercept for Patients with Wet Age-Related Macular Degeneration and Submacular Hemorrhage

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept
  • Sponsor:King's College Hospital NHS Foundation Trust

Study on Upadacitinib and Tocilizumab for Children and Teens with Active Systemic Juvenile Idiopathic Arthritis

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Tocilizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Study on CAR-T-cell Therapy with Rituximab and Ibrutinib for Patients with High-Risk Mantle Cell Lymphoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bendamustine
  • Sponsor:Klinikum Der Universitat Munchen AöR

Study Comparing Telisotuzumab Vedotin and Docetaxel for Adults with Previously Treated Non-Squamous Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Efficacy and Safety of Givinostat for Non-Ambulant Patients with Duchenne Muscular Dystrophy

Investigational
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Givinostat
  • Sponsor:Italfarmaco S.p.A.

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Bad Bramstedt

What the registry says about research in the country

01 Autoimmune Disorders

Innovative research focusing on systemic sclerosis treatment, investigating a novel subcutaneous therapy aimed at reducing skin sclerosis symptoms. These trials are evaluating new therapeutic approaches for managing this challenging autoimmune condition.

  • Skin sclerosis management
  • Subcutaneous administration methods
  • Novel therapeutic compounds

The research emphasizes improving treatment options for patients with progressive skin hardening and tissue fibrosis.

02 Rare Blood Disorders

Clinical investigations targeting Hypereosinophilic Syndrome, examining the effectiveness of new subcutaneous treatments for patients with uncontrolled disease states while maintaining standard care protocols.

  • Blood disorder management
  • Treatment resistance
  • Standard of care optimization

These studies aim to provide better therapeutic options for patients with rare eosinophilic conditions.

03 Inflammatory Conditions

Advanced research into systemic lupus erythematosus treatment, focusing on disease activity reduction and exploring new therapeutic compounds for this complex autoimmune disorder.

  • Disease activity assessment
  • Treatment safety evaluation
  • Long-term efficacy monitoring

The studies employ comprehensive assessment tools to measure treatment effectiveness in lupus patients.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.